← Back

Poolbeg Pharma PLC

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company based in London, United Kingdom, focused on developing immunotherapies for cancer. Its lead candidate, POLB 001, has completed a Phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and is in Phase 2 for the treatment of influenza. The company is also developing an oral encapsulated GLP-1R agonist for obesity and diabetes, as well as an AI-driven drug discovery program for therapies targeting influenza and respiratory syncytial viruses. Poolbeg Pharma PLC was incorporated in 2021.

Price · split & dividend adjusted
News & notes moving POLB.LSE
Critical Materials & Supply Chain▲

ACG Metals hits full-year oxide output target in six months

ACG Metals beat its full-year oxide production target in just six months, helped by a 64% jump in its realised gold price to $4,838 an ounce. First copper and zinc concentrate production is now expected in August. Rockfire Resources returned strong zinc and silver grades at its Molaoi project in Greece, with preliminary readings showing zinc values as high as 37.7%, and is fast-tracking feasibility studies and permit applications to reopen underground workings. Sunda Energy applied for a permit to explore an offshore area of New Zealand's Taranaki Basin covering around 645 square kilometres, triggering a three-month window for competing bids. CelLBxHealth remains on track for revenues of at least £2.1 million this year, up 50% on 2025, while searching for a new chief executive with no impact on trading expected. Poolbeg Pharma raised £3.5 million through a placing to fund two clinical trials and strengthen partnering discussions, extending its cash runway into the second quarter of 2028.
About megatrends
Critical Materials & Supply Chain › Precious Metals ▲Pricing
Critical Materials & Supply Chain › Copper ▲Supply
ACG.LSE · Supply · Positive Beat full-year oxide production target in six months, with first copper and zinc concentrate expected in August.
CLBX.LSE · Demand · Positive On track for revenues of at least £2.1 million this year, up 50% on 2025.
POLB.LSE · Capital · Positive Raised £3.5 million through a placing to fund two clinical trials and extend cash runway into Q2 2028.
ROCK.LSE · Technology · Positive Returned strong zinc and silver grades at Molaoi project, with zinc values as high as 37.7%, and fast-tracking feasibility studies.
SNDA.LSE · Regulation · Positive Applied for permit to explore offshore area in New Zealand's Taranaki Basin, triggering three-month window for competing bids.
Read original ↗
Yahoo Finance·82dRead more →